Your shopping cart is currently empty

Aldometanib (LXY-05-029) is an orally active aldolase inhibitor that prevents FBP from binding to v-ATPase-associated aldolase and activates lysosomal AMPK, useful in metabolic homeostasis research [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $35 | In Stock | In Stock | |
| 5 mg | $81 | In Stock | In Stock | |
| 10 mg | $129 | In Stock | In Stock | |
| 25 mg | $263 | In Stock | In Stock | |
| 50 mg | $423 | In Stock | In Stock | |
| 100 mg | $627 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $107 | In Stock | In Stock |
| Description | Aldometanib (LXY-05-029) is an orally active aldolase inhibitor that prevents FBP from binding to v-ATPase-associated aldolase and activates lysosomal AMPK, useful in metabolic homeostasis research [1]. |
| In vitro | Aldometanib (0-1000 nM; 2 h) activates AMPK through preventing aldolase from binding to FBP to engender a pseudo-starvation signal [1]. Western Blot Analysis [1] Cell Line: Mouse primary hepatocytes, MEFs cells Concentration: 0-1000 nM Incubation Time: 2 h Result: Activated AMPK in mouse embryonic fibroblasts (MEFs) and mouse primary hepatocytes cells. Immunofluorescence [1] Cell Line: MEFs cells Concentration: 5 nM Incubation Time: 2 h Result: Inhibited TRPVs and induces AXIN lysosomal translocation. |
| In vivo | Aldometanib, administered orally at dosages ranging from 0-10 mpk, effectively reduces blood glucose levels in lean mice and, when given at 2-10 mpk twice daily for a week, mitigates blood glucose and ameliorates fatty liver in obese hyperglycemic mice. Additionally, it addresses fatty liver and nonalcoholic steatohepatitis issues, and a regimen of 2 mpk twice daily over a month alleviates liver fibrosis in NASH mice. Moreover, Aldometanib extends the lifespan of C. elegans through the lysosomal pathway when administered orally at 0-50 μM for up to 50 days. In lean mice, dosages of 0-10 mpk lower fasting blood glucose, enhance glucose tolerance, and promote muscular TBC1D1 phosphorylation for glucose uptake. In obese hyperglycemic mice, a week-long administration of 2-10 mpk effectively lowers blood glucose, decreases hepatic TAG, and enhances insulin sensitivity through muscular AMPK dependencies, also diminishing fat mass. For NASH mice, a month-long administration of 2 mpk results in the reduction of NASH diagnostic histological scores, decreased hepatic cell apoptosis, reduced inflammatory liver responses, and improved glucose tolerance. In C. elegans, dosages of 0-50 μM improve oxidative stress resistance and bolster mitochondrial functions, while for C57BL/6 mice, administering 100 μg/mL orally rejuvenates muscle function and extends lifespan by increasing NAD+ levels and mitochondrial oxidative respiration. |
| Synonyms | Compound IA-47 (Br- base 2246625-81-8) |
| Molecular Weight | 593.46 |
| Formula | C27H43Cl2IN2 |
| Cas No. | 2904601-67-6 |
| Smiles | CC1=[N+](C=CN1CCCCCCCCCCCCCCCC)CC2=C(Cl)C=CC=C2Cl.[I-] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 131.25 mg/mL (221.16 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.